Approval · Notice of Compliance 22117 · 2019
ADCETRIS: Notice of Compliance 22117
Issued May 2, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22117
- Date
- May 2, 2019
- Company
- Seattle Genetics Inc
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for the treatment of previously untreated patients with Stage IV HL, in combination with doxorubicin, vinblastine, and dacarbazine.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADCETRIS | Not yet assigned | — |
Medicinal ingredients
- BRENTUXIMAB VEDOTIN 50 MG per VIAL